Status:
UNKNOWN
Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Lung Cancer
Healthy Human
Eligibility:
All Genders
18-80 years
Phase:
EARLY_PHASE1
Brief Summary
In the past three years, as the key protein suggested to be involved in host cell entry of SARS-CoV-2, studies of ACE2 aroused people's attention again. Tracking the expression of ACE2 in vivo is cruc...
Eligibility Criteria
Inclusion
- the ability to provide informed written consent
- a medical history without any ACE2-related comorbidities
Exclusion
- liver and renal function dysfunction,
- pregnancy or current lactation
Key Trial Info
Start Date :
November 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06194630
Start Date
November 30 2023
End Date
November 30 2025
Last Update
January 8 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science
Beijing, China
2
Peking Union Medical College Hospital
Beijing, China